Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients

References

• Malluche HH, Ritz E, Lange HP, et al. Bone histology in incipient and advanced renal failure. Kidney Int. 1976;9:355-62
   PubMed Web of Science ®Google Scholar
• Pitts TO, Piraino BH, Mitro R, et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 1988;67:876-81
   PubMed Web of Science ®Google Scholar
• Llach F, Yudd M. Pathogenic, clinical, and therapeutic aspects of secondary hyperparathyroidism in chronic renal failure. Am J Kidney Dis 1998;32:S3-12
   Web of Science ®Google Scholar
• Negri AL, Barone R, Quiroga MA, et al. Bone mineral density: serum markers of bone turnover and their relationships in peritoneal dialysis. Perit Dial Int 2004;24:163-8
   PubMed Web of Science ®Google Scholar
• Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis 2005;45:638-49
   PubMed Web of Science ®Google Scholar
• Terzibasioglu AM, Akarirmak U, Saridogan M, et al. Correlation of back pain, compression fracture and quadriceps muscle strength with bone mineral density in renal insufficiency patients. Eura Medicophys 2005;41:303-8
   PubMedGoogle Scholar
• Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2005;45:A5-7
   PubMed Web of Science ®Google Scholar
• Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489-95
   PubMed Web of Science ®Google Scholar
• Danese MD, Kim J, Doan QV, et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006;47:149-56
   PubMed Web of Science ®Google Scholar
• Johnson ES, Smith DH, Thorp ML, et al. Elevated intact parathyroid hormone levels and health care costs and utilization: retrospective cohort of patients with chronic kidney disease. Value Health 2006;9:A96 [abstract]
   Google Scholar
• Robbins JD, Kim JJ, Zdon G, et al. Resource use and patient care associated with chronic kidney disease in a managed care setting. J Managed Care Pharm 2003;9:238-47
   Google Scholar
• Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659-63
   PubMed Web of Science ®Google Scholar
• Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006;69:33-43
   PubMed Web of Science ®Google Scholar
• St. Peter WL, Lewis MJ, Collins AJ. End-stage renal disease. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy: a patholphysiologic approach, 5th edn. New York: McGraw-Hill, 2002 pp.815-42
   Google Scholar
• Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm 2007;13:397-411
   PubMed Web of Science ®Google Scholar
• 2003 ICD-9-CM professional for physicians – Volumes 1 & 2, 6th edn. Reston VA: Ingenix, 2003
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83
   PubMedGoogle Scholar
• Joyce AT, Iacoviello JM, Nag S, et al. End-stage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care 2004;27:2829-35
   PubMed Web of Science ®Google Scholar
• Kahn S. Secondary hyperparathyroidism is associated with high cost of care among chronic kidney disease patients with cardiovascular disease comorbidities. Nephron Clin Pract 2007;105:C159-64
   Google Scholar
• Horl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant 2004;19:V2-8
   PubMed Web of Science ®Google Scholar
• Friedman TC, Norris KC. The role of vitamin D in mild to moderate chronic kidney disease. Trends Endocrinol Metab 2002;13:189-94
   PubMed Web of Science ®Google Scholar
• Ho LT, Sprague SM. Renal osteodystrophy in chronic renal failure. Semin Nephrol 2002;22:488-93
   PubMed Web of Science ®Google Scholar
• Moe SM, Chen NX. Inflammation and vascular calcification. Blood Purif 2005;23:64-71
   PubMed Web of Science ®Google Scholar
• Floege J, Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant 2004;19:V59-66
   Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305
   PubMed Web of Science ®Google Scholar
• Tokumoto M, Tsuruya K, Fukuda K, et al. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor and cyclin-dependent kinase inhibitors, p21 and p27. Nephrol Dial Transplant 2003;18:iii9-12
   PubMedGoogle Scholar
• Tominaga Y, Kohara S, Namii Y, et al. Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg 1996;20:744-50
   PubMed Web of Science ®Google Scholar
• Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12
   PubMed Web of Science ®Google Scholar
• Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-8 [epub ahead of print 8 Nov 2006]
   PubMed Web of Science ®Google Scholar
• Pelletier EM, Shim B, Goodman S, et al. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis. Breast Cancer Res Treat 2008;108:297-305 [epub ahead of print 19 Jun 2007]
   PubMed Web of Science ®Google Scholar
• Fintel D, Joyce A, Mackell J, et al. Reduced mortality rates after intensive statin therapy in managed-care patients. Value Health 2007;10:161-9
   PubMed Web of Science ®Google Scholar